Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This study found that combining tamsulosin with finasteride was the most cost-effective treatment for mild to moderate BPH among the regimens tested.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

This article discusses the controversy surrounding finasteride, including claims of adverse effects like prostate cancer and permanent sexual dysfunction, but reports no new research findings.

This review addresses concerns about finasteride and high-grade prostate cancers but reports no new clinical results.

This study found that men who began balding at age 20 were twice as likely to develop prostate cancer later in life compared to those who did not experience early hair loss.

This review discusses various prostate cancer prevention strategies and reports no new clinical results; the authors highlight the need for ongoing research in this area.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.

This study reports that three synthesized PSMA-targeted radioimaging agents demonstrated high affinity and specific localization to prostate cancer tumors in a mouse model, highlighting their potential for cancer detection and monitoring.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

This study found that an earlier onset of androgenetic alopecia, especially in a frontal balding pattern, was significantly associated with an increased risk of prostate cancer among men at a Veterans Affairs Hospital.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

Finasteride treats hair loss but may affect prostate cancer detection.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

This study describes how robotic surgery has been widely adopted across various specialties in Hungary, showing benefits like lower complication rates and quicker recovery times, but also acknowledges challenges such as high costs and extended learning periods.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Gene variation affects prostate issues and hair loss.

This article outlines best practices from the World Professional Association for Transgender Health's standards to guide health care professionals in providing comprehensive care for transgender individuals, addressing mental health, endocrinology, and surgery.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.